dECTO CAR-NK

dECTO CAR-NK is an experimental natural killer (NK) cell therapy used as a negative control in the development of chimeric antigen receptor (CAR) treatments for T-cell malignancies. It consists of NK cells (typically the NK92 cell line or primary umbilical cord blood-derived NK cells) engineered with a CAR construct that lacks the functional extracellular antigen-binding domain (scFv). This truncation (denoted as 'dECTO' for deleted ectodomain) prevents the CAR from recognizing specific tumor antigens, such as CD5, while typically retaining the transmembrane and intracellular signaling domains (e.g., CD28, DAP10, and CD3z). Developed by researchers at the Korea Research Institute of Bioscience and Biotechnology (KRIBB) and the Korea Institute of Toxicology (KIT), dECTO CAR-NK is utilized in preclinical research to establish the baseline innate cytotoxicity of NK cells. This allows for the precise evaluation of the enhanced, antigen-specific anti-tumor activity and potential off-target toxicity of fully functional CAR-NK variants, such as OptiCAR-NK, in models of T-cell acute lymphoblastic leukemia (T-ALL).

Other names

dECTO controltruncated CD5 CAR-NKdECTO-NK92dECTO-NK-92dECTO-NK 92